drugset / Trial / NCT03582722

Weight Loss Aid in an Exposed Population

NCT03582722

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will explore whether the use of orlistat results in weight loss that is accompanied by a reduction in the body burdens of polybrominated biphenyls (PBB) and other Persistent Organic Pollutants (POPs).

Timeline

Start
2018-09-14
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Orlistat Small molecule 60 mg

Indications